Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Tables)

v3.10.0.1
Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets [Table Text Block]
The value of our amortizable intangible assets including gross asset value and carrying value is summarized below ($ in thousands):
 
 
 
Bertilimumab

iCo
 
 
NanomAbs

Yissum
 
 
Human

Antibodies

Kadouche
 
 
Anti-ferritin

Antibody

MabLife
 
 
Ceplene

Acquisition

Intangibles
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance as of December 31, 2017
 
$
1,419
 
 
$
383
 
 
$
381
 
 
$
318
 
 
$
3,976
 
 
$
6,477
 
Amortization
 
 
(126
)
 
 
(36
)
 
 
(23
)
 
 
(23
)
 
 
(461
)
 
 
(669
)
Impairment
 
 
-
 
 
 
-
 
 
 
(358
)
 
 
(295
)
 
 
-
 
 
 
(653
)
Balance, September 30, 2018
 
$
1,293
 
 
$
347
 
 
$
-
 
 
$
-
 
 
$
3,515
 
 
$
5,155
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gross asset value
 
$
2,509
 
 
$
694
 
 
$
-
 
 
$
-
 
 
$
4,310
 
 
$
7,513
 
Accumulated Amortization
 
 
(1,216
)
 
 
(347
)
 
 
-
 
 
 
-
 
 
 
(795
)
 
 
(2,358
)
Balance, September 30, 2018
 
$
1,293
 
 
$
347
 
 
$
-
 
 
$
-
 
 
$
3,515
 
 
$
5,155
 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Estimated amortization expense for each of the five succeeding years, based upon intangible assets at September 30, 2018 is as follows ($ in thousands):
 
Period Ending September 30,
 
Amount
 
2019
 
$
829
 
2020
 
 
829
 
2021
 
 
829
 
2022
 
 
829
 
2023
 
 
829
 
Thereafter
 
 
1,010
 
Total
 
$
5,155